Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities: 2012-2024

Historic Gains from Investment Securities for Ultragenyx Pharmaceutical (RARE) over the last 13 years, with Dec 2024 value amounting to $3.5 million.

  • Ultragenyx Pharmaceutical's Gains from Investment Securities fell 101.79% to -$30,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year decrease of 67.88%. This contributed to the annual value of $3.5 million for FY2024, which is 30.88% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Gains from Investment Securities of $3.5 million as of FY2024, which was down 30.88% from $5.0 million recorded in FY2023.
  • Ultragenyx Pharmaceutical's 5-year Gains from Investment Securities high stood at $37.1 million for FY2020, and its period low was $844,000 during FY2022.
  • Its 3-year average for Gains from Investment Securities is $3.1 million, with a median of $3.5 million in 2024.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Gains from Investment Securities crashed by 97.46% in 2021 and then surged by 498.10% in 2023.
  • Over the past 5 years, Ultragenyx Pharmaceutical's Gains from Investment Securities (Yearly) stood at $37.1 million in 2020, then crashed by 97.46% to $942,000 in 2021, then dropped by 10.40% to $844,000 in 2022, then skyrocketed by 498.10% to $5.0 million in 2023, then plummeted by 30.88% to $3.5 million in 2024.